Celcuity Inc
CELC54.600USD
+1.530+2.88%
收盘 09/17, 16:00（美东）报价延迟15分钟
2.12B总市值
亏损市盈率 TTM
关于 Celcuity Inc 公司
Celcuity Inc. 是一家临床阶段的生物技术公司，开发用于治疗多种实体肿瘤的靶向疗法。其主要治疗候选药物是 gedatolisib，这是一种强效的小分子可逆抑制剂，可选择性靶向所有 I 类磷脂酰肌醇-3-激酶 (PI3K) 亚型和两种雷帕霉素靶标 (mTOR) 亚复合物 mTORC1 和 mTORC2。其针对 gedatolisib 的初始临床开发计划专注于治疗激素受体阳性 (HR+)、人表皮生长因子受体 2 阴性 (HER2-) 或 HR+/HER2-、晚期或转移性乳腺癌患者以及转移性去势抵抗性前列腺癌患者。其 VIKTORIA-1 正在评估 gedatolisib 与氟维司群联合使用或不联合使用哌柏西利对 HR+/HER2- 晚期乳腺癌患者的疗效。其 CELsignia 伴随诊断平台能够分析活体患者肿瘤细胞，以识别新的癌症患者群体。
公司简介
公司代码CELC
公司名称Celcuity Inc
上市日期Sep 20, 2017
CEOMr. Brian F. Sullivan
员工数量87
证券类型Ordinary Share
年结日Sep 20
公司地址16305 36th Ave N Ste 100
城市MINNEAPOLIS
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编55446-4285
电话17633920767
网址https://www.celcuity.com/
公司代码CELC
上市日期Sep 20, 2017
CEOMr. Brian F. Sullivan
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.13M
+3.45%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
109.01K
+7.83%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月31日 周日
更新时间: 8月31日 周日
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
其他
52.40%
持股股东
持股股东
占比
Baker Bros. Advisors LP
18.66%
BVF Partners L.P.
8.17%
Sullivan (Brian F)
7.38%
Soleus Capital Management, L.P.
7.10%
Perceptive Advisors LLC
6.29%
其他
52.40%
股东类型
持股股东
占比
Hedge Fund
42.18%
Investment Advisor
19.01%
Individual Investor
11.21%
Investment Advisor/Hedge Fund
7.74%
Venture Capital
6.52%
Private Equity
6.33%
Research Firm
2.10%
Corporation
0.82%
Pension Fund
0.08%
其他
3.99%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
214
35.30M
87.21%
-4.75M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Innovator US Small Cap Managed Floor ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Morningstar Small-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares Hedge Replication ETF
0%
SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
查看更多
Innovator US Small Cap Managed Floor ETF
占比0%
Direxion Daily S&P Biotech Bull 3X Shares
占比0%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
SPDR S&P Biotech ETF
占比0%
Humankind US Stock ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
